CL2016002794A1 - Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico - Google Patents

Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico

Info

Publication number
CL2016002794A1
CL2016002794A1 CL2016002794A CL2016002794A CL2016002794A1 CL 2016002794 A1 CL2016002794 A1 CL 2016002794A1 CL 2016002794 A CL2016002794 A CL 2016002794A CL 2016002794 A CL2016002794 A CL 2016002794A CL 2016002794 A1 CL2016002794 A1 CL 2016002794A1
Authority
CL
Chile
Prior art keywords
peptide
chemotherapeutic agent
mutant ras
vaccine
cancer
Prior art date
Application number
CL2016002794A
Other languages
English (en)
Inventor
Jon Amund Eriksen
Gustav Gaudernack
Original Assignee
Targovax Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50679896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016002794(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Targovax Asa filed Critical Targovax Asa
Publication of CL2016002794A1 publication Critical patent/CL2016002794A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

<p>Se da a conocer al menos un péptido adecuado para provocar una respuesta inmune, para su uso en el tratamiento del cáncer. El, o cada, péptido corresponden a un fragmento de la proteína RAS, pero tiene de una a tres mutaciones puntuales de la misma. Al menos un péptido es para uso en el tratamiento del cáncer mediante la administración simultánea o secuencial con un agente quimioterapéutico antimetabolito.</p>
CL2016002794A 2014-05-06 2016-11-04 Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico CL2016002794A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14167265 2014-05-06

Publications (1)

Publication Number Publication Date
CL2016002794A1 true CL2016002794A1 (es) 2017-06-09

Family

ID=50679896

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002794A CL2016002794A1 (es) 2014-05-06 2016-11-04 Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico

Country Status (16)

Country Link
US (1) US9757439B2 (es)
EP (1) EP3140320B1 (es)
JP (2) JP2017514847A (es)
KR (1) KR20170002563A (es)
CN (1) CN106414493A (es)
AU (1) AU2015257774B2 (es)
BR (1) BR112016025764A2 (es)
CA (1) CA2947963A1 (es)
CL (1) CL2016002794A1 (es)
DK (1) DK3140320T3 (es)
ES (1) ES2716923T3 (es)
IL (1) IL248671B (es)
MX (1) MX2016014414A (es)
RU (1) RU2700929C2 (es)
SG (2) SG11201608712PA (es)
WO (1) WO2015169804A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3369432A1 (en) 2013-12-09 2018-09-05 Targovax Asa A peptide mixture
SG11201903674YA (en) 2016-10-26 2019-05-30 Modernatx Inc Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
JP2020514321A (ja) 2017-02-01 2020-05-21 モデルナティーエックス， インコーポレイテッド 活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物
WO2018145020A1 (en) * 2017-02-03 2018-08-09 The Medical College Of Wisconsin, Inc. Kras peptide vaccine compositions and method of use
BR112020025764A2 (pt) 2018-06-19 2021-05-11 Biontech Us Inc. neoantígenos e usos dos mesmos
WO2020002650A1 (en) 2018-06-29 2020-01-02 Targovax Asa A formulation
CN114681600A (zh) * 2018-10-19 2022-07-01 杭州纽安津生物科技有限公司 通用性多肽疫苗及其在制备治疗/预防胰腺癌药物中的应用
CA3141084A1 (en) * 2019-06-12 2020-12-17 Vikram JUNEJA Neoantigen compositions and uses thereof
CN113416241B (zh) * 2020-04-09 2022-04-08 北京臻知医学科技有限责任公司 一种用于诱导肿瘤特异性免疫响应的通用型抗原肽库及试剂盒
WO2022026620A1 (en) * 2020-07-29 2022-02-03 Sqz Biotechnologies Company Methods to stimulate immune responses to mutant ras using nucleated cells
EP4188425B1 (en) * 2020-07-29 2025-05-14 Stemcell Technologies Canada Inc. Methods to stimulate immune responses to mutant ras using anucleate cells
US20240000834A1 (en) * 2020-11-24 2024-01-04 Shanghai GenBase Biotechnology Co., Ltd. Ras mutant epitope peptide and t cell receptor recognizing ras mutant
JP2024541968A (ja) * 2021-10-28 2024-11-13 ジェネンテック， インコーポレイテッド 治療的介入のためにｍｈｃ関連抗原を同定するためのシステムおよび方法
WO2023220434A2 (en) * 2022-05-12 2023-11-16 The Johns Hopkins University Neoantigen vaccines for cancer prevention
WO2025103205A1 (en) * 2023-11-15 2025-05-22 Ck Life Sciences Development Limited Pharmaceutical compositions and methods for preventing or treating kras-associated diseases or conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103974D0 (en) * 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
GB2328689A (en) 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
NO309798B1 (no) * 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
CN102370974B (zh) 2002-12-16 2014-09-17 全球免疫股份有限公司 用于免疫治疗的基于酵母的疫苗
US20140199405A1 (en) * 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
EP3369432A1 (en) 2013-12-09 2018-09-05 Targovax Asa A peptide mixture

Also Published As

Publication number Publication date
RU2016147527A3 (es) 2019-01-21
AU2015257774A1 (en) 2016-12-22
US9757439B2 (en) 2017-09-12
MX2016014414A (es) 2017-02-23
EP3140320A1 (en) 2017-03-15
WO2015169804A1 (en) 2015-11-12
IL248671B (en) 2021-08-31
US20170065694A1 (en) 2017-03-09
BR112016025764A2 (pt) 2018-01-16
CN106414493A (zh) 2017-02-15
RU2700929C2 (ru) 2019-09-24
CA2947963A1 (en) 2015-11-12
AU2015257774B2 (en) 2018-12-20
JP7304629B2 (ja) 2023-07-07
KR20170002563A (ko) 2017-01-06
JP2017514847A (ja) 2017-06-08
IL248671A0 (en) 2017-01-31
SG11201608712PA (en) 2016-11-29
EP3140320B1 (en) 2018-12-26
RU2016147527A (ru) 2018-06-08
JP2020100650A (ja) 2020-07-02
SG10201809701TA (en) 2018-12-28
DK3140320T3 (en) 2019-04-15
ES2716923T3 (es) 2019-06-18

Similar Documents

Publication Publication Date Title
CL2016002794A1 (es) Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico
CY1123845T1 (el) Τοπικα φαρμακευτικα σκευασματα για την αγωγη φλεγμονωδων καταστασεων
MX2019008350A (es) Formulaciones de anticuerpos de her2 subcutáneas.
CL2016002269A1 (es) Moduladores alostéricos del núcleo proteico de la hepatitis b.
SV2018005610A (es) Derivados de oxopiridina sustituidos
MX378273B (es) Compuestos activos hacia bromodominios.
MX2017004708A (es) Tratamiento del cáncer con agonista de tlr9 con inhibidores de punto de control.
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
MX2015016627A (es) Vacuna para la malaria.
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
PL3896064T3 (pl) Pochodne 4,6-diamino-chinolino-3-karbonitrylu jako modulatory cot w leczeniu choroby leśniowskiego-crohna i wrzodziejącego zapalenia jelita grubego
MX392779B (es) Anticuerpos anti-cd27
MX2015009105A (es) Composiciones en solucion solida y su uso en inflamacion cronica.
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CY1119957T1 (el) Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος
CO2018008445A2 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-deca
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MX389026B (es) Una composicion farmaceutica y el uso de la misma.
MX2017000676A (es) Oritavancina de alta pureza y metodo para producir la misma.
MX386606B (es) El uso de una vacuna para la prevención de diarrea epidémica porcina.
HUE059630T2 (hu) Nátrium-fenil-butirátot tartalmazó, kellemes ízû készítmények és alkalmazásaik
BR112016006210A2 (pt) terapia e vacina contra gripe
EA201691638A1 (ru) Новые способы индуцирования иммунного ответа
EA201691860A1 (ru) Пептидный медикамент в виде сухого порошка
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina